Premium
Characterization of IgG monoclonal anti‐cardiolipin/anti‐β 2 GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies
Author(s) -
Zhu Min,
Olee Tsaiwei,
Le Dzung T.,
Roubey Robert A. S.,
Hahn Bevra H.,
Woods, Jr Virgil L.,
Chen Pojen P.
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1999.01292.x
Subject(s) - antibody , monoclonal antibody , cardiolipin , antiphospholipid syndrome , subclass , immunology , lupus anticoagulant , monoclonal , immunofluorescence , microbiology and biotechnology , medicine , biology , biochemistry , phospholipid , membrane
Antiphospholipid antibodies (aPL), including antibodies detected in anti‐cardiolipin (aCL) enzyme‐linked immunosorbent assays and in lupus anticoagulant (LA) tests, are strongly associated with recurrent thrombosis and recurrent fetal loss, i.e. the antiphospholipid syndrome (APS). Although recent studies suggest that most APS‐associated aCL are directed against the phospholipid (PL)‐binding plasma protein β 2 ‐glycoprotein 1 (β 2 GP1), the precise nature of aCL binding specificities remains controversial. To address the issue of aCL specificity we generated five new monoclonal IgG aCL from two patients with APS. Characterization of these five aCL, as well as two previously published IgG aCL, revealed three patterns of reactivity: (1) four antibodies reacted strongly with human β 2 GP1‐cardiolipin (CL) complexes and weakly with human β 2 GP1 alone; (2) two antibodies recognized bovine β 2 GP1, but not human β 2 GP1; (3) one antibody reacted with complexes of human β 2 GP1 and CL, but not with human β 2 GP1 alone. Only one monoclonal displayed weak LA activity. These patient‐derived IgG monoclonal antibodies, and additional ones to be generated, may help define varying species of antibodies detected in aCL assays and identify the specific antibodies that may be pathogenic.